A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IMDC / International mRCC Database Consortium

[Related PubMed/MEDLINE]
Total Number of Papers: 27
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IMDC  (>> Co-occurring Abbreviation)
Long Form:   International mRCC Database Consortium
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. mOS, mRCC, ORR, OS, TTF
2021 Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. CI, IO, mOS, mRCC, mTTD, ORR
2021 Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). C-index, CN, mRCC, MSKCC, OM, REMARCC
2021 Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. ICI, mRCC, ORR, OS, TNT, TTF
2021 Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. mRCC, OS
2021 External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study. CN, IPTW, mRCC, OS, REMARCC, TKIs
2021 Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. MLR, mRCC, MVA, OS, PFS
2021 Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. CI, ICIs, mRCC, ORR, OS, PFS
2021 Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. CI, mRCC, ORR, OS, PFS, uCN
10  2021 Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma. DLCT, IC, mRCC, ORR, OS, PFS
11  2020 Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. BV, C-index, DCE-CT, mRCC, OS, PFS
12  2020 Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. IPTW, mRCC, Nivo-Ipi, TKIs
13  2020 Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. CGA, mRCC, TKIs
14  2020 Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. CI, CN, dCN, HR, mRCC, OS, TTF
15  2020 Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumour-infiltrating lymphocytes. mRCC, TILs, TIMs
16  2018 Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. HR, mRCC, OS, PFS, RCC
17  2018 Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. IS, mRCC, sPD-L1
18  2018 Real-world evidence in metastatic renal cell carcinoma. ---
19  2018 [EFFICACY AND SAFETY OF PAZOPANIB FOR ADVANCED OR METASTATIC RENAL CELL CARCINOMA: A SINGLE-INSTITUTION STUDY]. AEs, BR, OS, PD, PFS, PR, RCC, SD
20  2017 Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib. mRCC, OS, PFS
21  2017 Characterizing the outcomes of metastatic papillary renal cell carcinoma. mRCC, ORR, OS, PFS, PRCC
22  2017 Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents. mRCC, MSKCC, OS, TTF
23  2016 First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. CI, HR, mRCC, OS, PFS, PZ, RR, SU
24  2015 A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. IT, LLN, mRCC, OS, TKI
25  2014 Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. LTS, mRCC, non-PD, OS, STS
26  2014 Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. CQRM, first-line, mccRCC, mTORi, PFS, TKI, TTF
27  2013 Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. ccRCC, nccRCC, OS, TTF